SCHEMBL2554274

SCHEMBL2554274

COCCn1c(-c2c[nH]c(-c3ccc(Cl)cc3)n2)nc2cnccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 1/20 0.45
▸ BRD4 O60885 1/20 0.42
▸ ALDH1A1 P00352 8/20 0.42
▸ HSD17B10 Q99714 5/20 0.42
▸ CYP1A2 P05177 5/20 0.42
▸ HPGD P15428 4/20 0.42
▸ CASP1 P29466 4/20 0.42
▸ CASP7 P55210 4/20 0.42
▸ CYP3A4 P08684 3/20 0.42
▸ CYP2C9 P11712 3/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ CASR P41180 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ RECQL P46063 1/20 0.39
▸ CYP2D6 P10635 3/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ MAP4K4 O95819 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2554431 0.87 HPGD (0.57) RIPK2BRD4ALDH1A1HSD17B10HPGD
SCHEMBL14575950 0.85 RIPK2 (0.49) RIPK2ALDH1A1HSD17B10HPGDCASR
SCHEMBL14575975 0.83 RIPK2 (0.43) RIPK2BRD4ALDH1A1HSD17B10CYP1A2
SCHEMBL12284277 0.82 RIPK2 (0.64) RIPK2BRD4ALDH1A1HSD17B10CYP1A2
SCHEMBL14576869 0.81 KDM4E (0.49) RIPK2BRD4ALDH1A1HSD17B10CYP1A2
SCHEMBL14576556 0.81 CNR2 (0.50) RIPK2ALDH1A1HSD17B10HPGDCASR
SCHEMBL12284533 0.80 RIPK2 (0.56) RIPK2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL12284274 0.80 RIPK2 (0.57) RIPK2
SCHEMBL14576160 0.79 RIPK2 (0.59) RIPK2KDM4E
SCHEMBL14576575 0.79 CASR (0.58) RIPK2ALDH1A1HSD17B10CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 — — EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885BRD4 551/4885ALDH1A1 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback